| Literature DB >> 24819955 |
Guozheng Huang1, Beata Kling2, Fouad H Darras2, Jörg Heilmann2, Michael Decker3.
Abstract
Two sets of carbamates based on the natural alkaloid evodiamine were designed, synthesized and evaluated as potential butyrylcholinesterase inhibitors. Although a set of carbamates of 3-hydroxyevodiamine (10a-f) is inactive both at AChE and BChE, carbamates of 5-deoxo-3-hydroxyevodiamine (11a-f) exhibit much better potency with selectivity toward BChE. The heptyl carbamate of 5-deoxo-3-hydroxyevodiamine (11c) shows the best potency with an IC50 value of 77 nM and very good selectivity over AChE. ORAC and cell-based assays indicate 11c owns pronounced antioxidant properties with 1.75 Trolox equivalents and strong neuroprotection even from 1 μM onwards. These combined activities might enable compound 11c to be a potential candidate for treatment of Alzheimer's disease.Entities:
Keywords: Alzheimer's disease; Butyrylcholinesterase inhibitor; Carbamates; Evodiamine; Neuroprotection
Mesh:
Substances:
Year: 2014 PMID: 24819955 DOI: 10.1016/j.ejmech.2014.05.002
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514